Antidepressant pharmacotherapy in old-age depression-a review and clinical approach
- PMID: 28280892
- DOI: 10.1007/s00228-017-2219-1
Antidepressant pharmacotherapy in old-age depression-a review and clinical approach
Abstract
Purpose: Depression in old age is a disabling disease associated with functional and cognitive decline severely affecting quality of life. Studies specifically investigating antidepressant treatment for this special cohort of patients remain scarce and results are often conflicting. A narrative literature review was undertaken, synthesizing findings from published studies, systematic reviews, and treatment guidelines specifically conducted in elderly depressed patients to summarize implications and current recommendations as well as gaps in evidence for old-age pharmacologic treatment.
Methods: PubMed and Medline databases were searched for articles from July 2011 to July 2016. Only RCTs, meta-analyses, systematic reviews, and treatment guidelines focussing on the effect of antidepressant pharmacotherapy in old-aged participants were extracted, analysed, and discussed. The search resulted in a total of 26 articles.
Results: Selective serotonin reuptake inhibitors (SSRIs) and other second-generation antidepressants are recommended for first-line treatment of old-age depression. The differences in efficacy and tolerability within different substances and substance classes are minimal or non-existent. Tricyclic antidepressants (TCAs) are only considered for second-line treatment, due to their cardiac risk profile and anticholinergic effects. In treatment-resistant depression, augmentation therapy options include lithium and atypical antipsychotics.
Conclusions: There is convincing evidence that antidepressants are efficacious in the treatment of old-age depression and that rationales are necessary for treatment planning. However, evidence-based data on recovery and remission rates in old-age depression specific to certain antidepressant drugs are still missing in trials and are of great importance for pharmacological treatment of old-age depression in daily clinical practice.
Keywords: Antidepressant pharmacotherapy; Depression; Old age.
Similar articles
-
If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.Drugs. 2011 Jan 1;71(1):43-64. doi: 10.2165/11587620-000000000-00000. Drugs. 2011. PMID: 21175239 Review.
-
Using antipsychotic agents in older patients.J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. J Clin Psychiatry. 2004. PMID: 14994733 Review.
-
Treatments for late-life bipolar disorder.Am J Geriatr Pharmacother. 2006 Dec;4(4):347-64. doi: 10.1016/j.amjopharm.2006.12.007. Am J Geriatr Pharmacother. 2006. PMID: 17296540 Review.
-
Augmentation strategies for treatment-resistant depression.Curr Opin Psychiatry. 2009 Jan;22(1):7-12. doi: 10.1097/YCO.0b013e32831be9ef. Curr Opin Psychiatry. 2009. PMID: 19122528 Review.
-
Evidence-based pharmacotherapy of treatment-resistant unipolar depression.Int J Psychiatry Clin Pract. 2017 Mar;21(1):13-23. doi: 10.1080/13651501.2016.1248852. Epub 2016 Nov 16. Int J Psychiatry Clin Pract. 2017. PMID: 27848269 Review.
Cited by
-
Systematic Review: Depression and Anxiety Prevalence in Bladder Cancer Patients.Bladder Cancer. 2018 Jul 30;4(3):319-326. doi: 10.3233/BLC-180181. Bladder Cancer. 2018. PMID: 30112443 Free PMC article.
-
Ghrelin/GHSR System in Depressive Disorder: Pathologic Roles and Therapeutic Implications.Curr Issues Mol Biol. 2024 Jul 10;46(7):7324-7338. doi: 10.3390/cimb46070434. Curr Issues Mol Biol. 2024. PMID: 39057075 Free PMC article. Review.
-
Age as a moderating factor of treatment resistance in depression.Eur Psychiatry. 2023 Apr 20;66(1):e35. doi: 10.1192/j.eurpsy.2023.17. Eur Psychiatry. 2023. PMID: 37078509 Free PMC article.
-
Needs and Needs Communication of Nursing Home Residents with Depressive Symptoms: A Qualitative Study.Int J Environ Res Public Health. 2022 Mar 19;19(6):3678. doi: 10.3390/ijerph19063678. Int J Environ Res Public Health. 2022. PMID: 35329364 Free PMC article.
-
Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders.Front Pharmacol. 2021 Feb 4;11:618065. doi: 10.3389/fphar.2020.618065. eCollection 2020. Front Pharmacol. 2021. PMID: 33613284 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical